Breakthrough vaccine targets pancreatic cancer cells, showing promise in preclinical trials and paving the way for human testing.

Researchers at Case Western Reserve University and Cleveland Clinic are developing vaccines targeting pancreatic cancer that could eliminate the disease, leaving a patient cancer-free. So far, the ...

Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI in EGFR-mutated advanced/metastatic non-small cell lung cancer. KEYMAKER-U01 substudy 01A: Phase 1/2 study of pembrolizumab plus ...

About IO Biotech IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform.

Insights from DNA Cancer Vaccine Trials Using Needle-Free Injection Delivery, the presentation will share data showing that PharmaJet technology can induce robust T cell responses and tumor/lesion ...

PGV001, a personalized cancer vaccine, induced immune responses across various cancer types like breast and urothelial cancer, as well as multiple myeloma.

mRNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

A vaccine kept patients free of pancreatic cancer for years, yet new reports say the NIH is advising against mentioning mRNA tech in grants.

A vaccine to prevent breast cancer is showing good results, and moving into the next stage of clinical trials.

The five-year survival rate of people diagnosed with pancreatic cancer is currently 13 percent. Two breakthroughs are bringing hope for successfully treating this malignancy.

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.

Personalized mRNA vaccines show promise as a pancreatic cancer treatment, according to a small, early stage trial published Wednesday.